Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits in the top decile of US sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: 138 sponsored US clinical trials, 4 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sponsors 138 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 101 completed. 4 of these trials are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cancer, with 2 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University ranks in the top decile of sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
101 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
138 total, page 2 of 3
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02566304
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
NCT02583893
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02569957
Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors
NCT03054025
Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
NCT02989623
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
NCT03198286
Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer
NCT02517268
Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer
NCT02467738
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
NCT02318771
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
NCT02186509
Genetic Evaluation of Men (GEM)
NCT03076242
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02224729
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
NCT02245100
Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy
NCT02170350
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
NCT01938833
Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy
NCT02115607
Educational Module and Decision Counseling Program in Increasing Mammography Screening Rates in Formerly Homeless Women With Serious Mental Illness
NCT03162887
Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy
NCT02153151
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
NCT01982682
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
NCT01972737
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
NCT02083692
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
NCT01848067
Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery
NCT02603965
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
NCT01869114
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01871441
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT01818063
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01822015
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
NCT01819233
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
NCT01760655
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
NCT01703507
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
NCT01878695
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
NCT01324635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
NCT01532635
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
NCT01437488
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
NCT01550523
Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery
NCT02579551
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
NCT01458366
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
NCT01420250
Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy
NCT03013413
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy
NCT01369641
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
NCT01384513
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
NCT01313559
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
NCT01356628
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
NCT01352312
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
NCT01350258
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
NCT01349101
Digoxin for Recurrent Prostate Cancer
NCT01162135
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
NCT01184885
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
NCT01350245
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
NCT01184898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 41 |
| Phase 3 | 4 |
What is open in the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline
4 recruiting of 138 indexed (3% open); 101 completed (73%).
Phase mix: 4 late (III/IV) vs 93 early (I/II) (early-phase heavy).
Top condition: Pancreatic Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: open-pipeline peers nationwide
Peers matched on 138 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 138 trials (± recruiting share)
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Barbara Ann Karmanos Cancer Institute · 139 trials · 12% recruiting
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University page
138 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University or any single study.
- 4 of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pancreatic Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline card: 138 registered trials from official public datasets.Report a data error.